About Us
Real-time Quotes & News
Market Analysis
Trading Platform
Terms
Promotion
FAQ
Contact
繁
简
EN
繁
简
EN
Promotion
FAQ
Contact
Open Account
Contact Us

HSBC lowered its target price for Nvidia (NVDA.O) from $320 to $310.

2026-02-24

HSBC lowered its target price for Nvidia (NVDA.O) from $320 to $310.

Other News
2026-02-24

In a letter to Hungarian Prime Minister Viktor Orbán, European Council President Costa stated that decisions made by the European Council must be respected. Any breach of this commitment would constitute a violation of the principle of genuine cooper

In a letter to Hungarian Prime Minister Viktor Orbán, European Council President Costa stated that decisions made by the European Council must be respected. Any breach of this commitment would constitute a violation of the principle of genuine cooperation.
2026-02-23

Key News: 1. Nasdaq: Winter storms have no impact on markets and systems. 2. U.S. Customs will cease collecting tariffs ruled illegal by the Supreme Court starting February 24. 3. Market news: Given the tariff risks posed by U.S. President Trump,

Key News: 1. Nasdaq: Winter storms have no impact on markets and systems. 2. U.S. Customs will cease collecting tariffs ruled illegal by the Supreme Court starting February 24. 3. Market news: Given the tariff risks posed by U.S. President Trump, the EU plans to freeze the approval process for trade agreements with the U.S. 4. Federal Reserve Governor Waller: My stance on whether to cut rates in March or keep rates unchanged is like a "coin toss," which will heavily depend on February employment data. 5. Trump claims the Supreme Court's tariff ruling inadvertently gave him "more power," threatening to implement "more severe and destructive" tariff measures. Stock News: 1. AMC Theatres (AMC.N) announces the issuance of $1.73 billion in first lien notes. 2. Market news: Paramount's revised offer for Warner Bros. Discovery (WBD.O) may be $32 per share. 3. Novo Nordisk (NVO.N) stated that its canagliflozin (Cagrisema) failed to meet the efficacy criteria for non-inferiority to Eli Lilly's zepbound in clinical trials. 4. Cancer cell therapy company Arcellx saw a surge in pre-market trading following news that Gilead Sciences is reportedly set to acquire the company for $115 per share. 5. Merck (MRK.N) plans to split its human health business into two divisions to alleviate operational pressure from the expiration of the patent on its best-selling drug Keytruda.
Open Account
Demo Account
Contact Us
About Us Real-time Quotes & News Market Analysis
 Trading Platform Market Analysis Promotion Terms Promotion FAQ Contact
Copyright © 2026 Aspire Global Company Limited. All Rights Reserved.
Terms of Use and Privacy
Disclaimer

Disclaimer: ASPIRE is not responsible for the content of any analysis, advice, comment, suggestion, research report or market data in this website and links to third-party websites or resources. All the information mentioned above only represents the view of corresponding author. ASPIRE cannot and does not warrant the accuracy, validity, timeliness or completeness of any such information. You should conduct individual assessments and other proper research to make their investment decisions. The materials and information contained in this website are provided for reference only and do not constitute or form an offer, invitation, solicitation or investment advice or recommendation to acquire or dispose of any investment products or services. The price of any financial instruments described in this website may fall as well as rise. Past performance should not be taken as an indication of future performance. The risk disclosure statements do not purport to disclose or discuss all of the risks and other significant aspects of any financial instruments mentioned in this website. You should make your own appraisal of the risk and should consult to the extent necessary your own legal, tax, financial or other professional advisers in respect of any financial instruments mentioned in this website prior to entering into any transaction.

Risk Warning: Leveraged Precious Metals trading on margin carries significant risks and is not suitable for all investors. Please be sure to make investments within your own tolerance after fully understand the risks involved.

Registered & Business Address: Room 1905-1906, 19/F, Eastern Commercial Centre, 395-399 Hennessy Road, Hong Kong

Aspire Global Company Limited is not available to provide services for the residents of certain jurisdictions such as Afghanistan, the United States of America, the Islamic Republic of Iran, North Korean.